Effects of Diane-35 and metformin on the concentrations of anti-Müllerian hormone in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038695

Enrollment

Unknown

Registered

2020-09-28

Start date

2014-01-01

Completion date

Unknown

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Hyperandrogenemia and normal insulin group:Diane-35

Hyperinsulinemia and normal androgen group:metformin

Hyperandrogenemia and hyperinsulinemia group:Diane-35 and metformin

Eligibility

Sex/Gender

Female

Age

19 Years to 35 Years

Inclusion criteria

Inclusion criteria: Women with PCOS that were 19-35 years of age, with biochemical HA and/or hyperinsulinemia were enrolled. The 2003 Rotterdam criteria wrs used for a diagnosis of PCOS.

Exclusion criteria

Exclusion criteria: Exclusion criteria included hyperprolactinemia and thyroid dysfunctionas well as other causes of HA, including Cushing syndrome, an androgen secreting tumor, and ovulation induction prior to the study. Patients were also excluded if they wished to conceive.

Design outcomes

Primary

Measure	Time frame
anti-Müllerian hormone;	—

Countries

China

Contacts

Public ContactChunxia Fang

Jiaxing Maternity and Child Health Care Hospital

facx2015@hotmail.com+86 18457315157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026